Why this poison is interesting

The adder is the one envenomation in this library, and it earns its place because it inverts two clinical instincts. A limb that swells dramatically over hours, tense and bruised, looks like a surgical emergency — and it almost never is: adder venom produces swelling by making vessels leak, not by the mechanism of a true compartment syndrome, and cutting it is usually the wrong move.¹ Meanwhile the feature that actually threatens life is undramatic and early: a transient anaphylaxis-like systemic reaction — vomiting, angio-oedema, hypotension, collapse — that can occur within minutes of the bite and then settle, only to be underestimated.

Vipera berus is the only venomous snake native to Britain, so this is the snakebite a UK emergency clinician will actually see. The UK National Poisons Information Service ran a five-year prospective audit of the national antivenom, ViperaTAb, and its findings anchor this page: of 170 patients given antivenom, systemic envenoming was present in about 38%, the initial dose was judged effective in about 72%, repeat dosing was common — mostly for worsening local swelling — and there were no deaths.¹ The adder is dangerous enough to warrant respect and antivenom, and rarely dangerous enough to kill a treated patient.

The toxic principle

Unlike every other page in this library, the toxic species here is not a small molecule but a protein venom — a complex, enzymatically active mixture. Viper venoms are dominated by snake venom metalloproteinases (SVMPs), zinc-dependent enzymes that degrade the basement membrane and the structural proteins of vascular endothelium, together with phospholipase A₂ enzymes and serine proteases. It is enzymes, not a toxin, doing the damage, and that changes the shape of the poisoning.

The same vascular action, when enough venom reaches the circulation, drives the systemic picture: a generalised increase in vascular permeability and mediator release producing hypotension and angio-oedema — an anaphylaxis-like reaction that is a direct venom effect rather than a true IgE-mediated allergy, although the two are clinically similar.¹ Phospholipase A₂ and other components contribute to the local tissue damage and to less common systemic effects; significant coagulopathy and acute kidney injury are described but are relatively uncommon in V. berus compared with some exotic vipers.

Toxicokinetics

The kinetic frame here is not a small molecule's absorption and clearance but venom in versus antivenom in. Venom is deposited in tissue and reaches the circulation largely by the lymphatics; the antivenom is an ovine Fab fragment whose own kinetics explain why the poisoning can recur and why repeat dosing is common.

Adder envenoming — venom and antivenom, not a drug
Parameter	Therapeutic	In overdose	Why it changes
Venom delivery	Injected into subcutaneous tissue; spreads locally and reaches the circulation via lymphatics. Envenoming is not invariable — 'dry' or minimal bites occur	A larger venom load produces more extensive local and more likely systemic effects	Because uptake is partly lymphatic and progressive, local effects evolve over hours, so a modest early appearance does not exclude significant later swelling.
Systemic onset	The anaphylaxis-like reaction can occur within minutes of the bite; median time to hospital presentation in the UK audit was about 2 h¹	Early systemic collapse is the time-critical event	The early reaction may be transient and self-terminating, which is exactly why it is underestimated; it can also recur.
Antivenom (ViperaTAb)	Ovine Fab fragment, monospecific for V. berus. Fab fragments are relatively small and are cleared renally, giving a shorter half-life than whole IgG antivenoms²	The short Fab half-life is why envenoming can recur as antivenom is cleared while venom persists	In the UK audit, repeat dosing occurred in about a third of patients, predominantly for persisting or worsening local effects — the clinical counterpart of Fab being cleared before the venom is gone.¹ Inferred
Dialysability	—	Not applicable. The problem is a protein venom neutralised by antivenom, not a dialysable toxin	There is no removal-based therapy; the specific treatment is immunological neutralisation with antivenom.

Metabolism and the metabolites

There is no metabolism in the usual sense — no bioactivation, no toxic metabolite. The 'pathway' for an envenomation is the venom's enzymatic action on host tissue: the metalloproteinases and phospholipases act directly on the victim's vasculature and cells, and the antivenom intercepts free venom before it can bind.

Adder venom — enzymes acting on the host, and where antivenom intervenes

Venom injected (metalloproteinases · PLA₂ · serine proteases)The toxic species is a protein mixture acting enzymatically
Capillary leak → local oedema, bruising, blisteringThe swelling is leak, not compartment obstruction
Venom reaching the circulation (larger loads)Systemic permeability + mediator releaseAnaphylaxis-like hypotension and angio-oedema — the life threat¹
Antivenom (ovine Fab) binds free venomNeutralised venom–Fab complex, renally clearedIntercepts free venom — but short Fab half-life allows recurrence²

Elimination and accumulation

The clinically important 'elimination' is the mismatch between two clocks: venom persists in the tissues and continues to be released, while the Fab antivenom is cleared relatively quickly. When the antivenom is gone before the venom is, the envenoming can recur or progress, which is the mechanistic basis for the repeat dosing seen in about a third of the UK audit's patients — overwhelmingly for persisting or worsening local swelling rather than for renewed systemic features.¹ This is the same recurrence logic that appears with Fab therapy elsewhere in the estate, and it is why observation after antivenom must continue rather than ending with the first apparent response.

Target organs — and why those

Bitten limb — skin, soft tissue and microvasculature

TargetVascular basement membrane and endothelium, digested by metalloproteinases

Why hereThe venom is deposited here and acts locally first, so the bitten limb bears the brunt: progressive oedema from capillary leak, ecchymosis and blistering. The appearance is dramatic because the leak is extensive, but it is permeability injury, not ischaemic compartment failure. Established

At the bedsidePain and progressive swelling, often spreading beyond a major joint over hours; management is elevation, analgesia and observation, with antivenom for marked or progressing swelling — not fasciotomy.¹

Systemic vasculature

TargetEndothelial permeability throughout the circulation, plus mediator release

Why hereWhen enough venom reaches the circulation the same permeability action becomes generalised, producing hypotension and angio-oedema — an anaphylaxis-like reaction that is a direct venom effect. This is the organ system that kills, and it declares early. Established

At the bedsideEarly vomiting, angio-oedema, hypotension and collapse; present in about 38% of the audit's antivenom-treated patients and the principal indication for antivenom.¹

Blood and kidney (less commonly)

TargetCoagulation cascade and renal function, via venom enzymes and shock

Why hereSerine proteases and metalloproteinases can perturb coagulation, and hypotension or direct effects can injure the kidney, but significant coagulopathy and AKI are relatively uncommon with V. berus compared with some exotic vipers. Inferred

At the bedsideLeucocytosis is commonly reported and is a recognised marker of significant envenoming (a definite leucocytosis is itself an antivenom indication); overt coagulopathy and AKI are less frequent and, when present, indicate severe envenoming.¹

Timeline of effects

Adder bite — early systemic risk, evolving local swelling

Time

What you seeWhat is happening

MinutesImmediate
What you seeLocal pain; in a minority, an early anaphylaxis-like reaction — vomiting, angio-oedema, hypotension, collapse.
What is happeningVenom deposited in tissue; a portion reaching the circulation triggers systemic permeability and mediator release. This early reaction is the main life threat.
HoursLocal progression
What you seeSwelling spreads up the limb, often beyond a major joint, with bruising and blistering; leucocytosis.
What is happeningMetalloproteinases continue to digest vascular scaffolding; lymphatic spread extends the affected area. The swelling is leak, not compartment obstruction.
Hours–daysTreatment and recurrence
What you seeAntivenom for systemic or marked local envenoming; swelling may worsen again as antivenom is cleared, prompting repeat dosing.
What is happeningFab antivenom neutralises free venom but is cleared faster than the venom is eliminated, so envenoming can recur — the basis for the common repeat dose.¹
Days–weeksResolution
What you seeSwelling and bruising resolve slowly; residual limb dysfunction can persist for weeks in severe local envenoming.
What is happeningTissue repair after the enzymatic injury; the prolonged recovery reflects the extent of the local damage rather than persisting venom.

What the mechanism predicts at the bedside

Resist fasciotomy for the swollen limb. The swelling is venom-induced capillary leak, not the ischaemic compartment syndrome its appearance mimics; the UK audit explicitly advises avoiding unnecessary surgery, and NPIS discussion can help prevent it.¹
Treat the early systemic reaction as the emergency. The anaphylaxis-like hypotension and angio-oedema is the feature most likely to kill, can occur within minutes, and can be transient — a settling episode is not a resolved one.¹
Antivenom is for systemic envenoming or marked/progressing local swelling, and it works — judged effective for the initial dose in about 72% of the audit's patients; it should be given as early as the indication is met, in discussion with NPIS.¹
Expect possible recurrence and repeat dosing. Because the Fab antivenom is cleared faster than the venom, worsening local swelling after an initial response is common and is a reason to re-dose, not a treatment failure.¹
Not every bite envenomates. 'Dry' and minimal bites occur, and local effects evolve over hours, so both over- and under-reaction are avoided by observation and NPIS-guided assessment rather than by the first appearance.

The antidote, from the poison's side

The antidote here is an antivenom — the purest example in the estate of neutralising a poison by binding it, because the poison is itself a set of proteins against which antibodies can be raised.

There is no drug-monograph page for the antivenom on the sibling drug site, so it is named here rather than linked, and its indications, dose and re-dosing are set with NPIS. The wider point for the library is structural: the adder is the one poisoning whose 'antidote' is an antibody against the poison itself, which is the cleanest possible version of the binding-antidote idea that foxglove approximates with digoxin-specific Fab and that death cap explicitly lacks.

Critical appraisal

The antivenom evidence is observational. The UK audit is prospective, national and the best available, and it supports effectiveness and safety with no deaths in 170 treated patients — but it is not a controlled trial, and 'effective' rests on clinician assessment rather than a randomised comparator.¹ Established
The 38% systemic and 72% initial-efficacy figures describe an antivenom-treated cohort, not all adder bites. They apply to patients selected for antivenom, so they should not be read as the rate of systemic envenoming among all bites, most of which are milder and never reach antivenom.¹
The 'no fasciotomy' teaching is well supported and important, but not absolute. The audit and UK guidance advise against unnecessary surgery, and the swelling is a permeability injury rather than compartment syndrome; a genuine compartment syndrome remains theoretically possible and would be a clinical, not reflexive, diagnosis.¹² Established
The venom-composition mechanism is general viperid pharmacology. That metalloproteinases and phospholipase A₂ drive the local and systemic permeability effects is well established for viper venoms and applied here to V. berus; the precise contribution of each component to each clinical feature in the adder specifically is an extension of that general knowledge. Inferred

References

1
Lamb T, Stewart D, Warrell DA, Lalloo DG, Jagpal P, Jones D, Thanacoody R, Gray LA, Eddleston M. Moderate-to-severe Vipera berus envenoming requiring ViperaTAb antivenom therapy in the UK. Clinical Toxicology (Philadelphia) 2021;59(11):992–1001. PMID 33720783.
2
Warrell DA. Treatment of bites by adders and exotic venomous snakes. BMJ 2005;331(7527):1244–7. PMID 16308385.

Adder envenomation (Vipera berus)

At a glance